Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer

• Main Authors: Felix Preisser, Felix. K.-.H. Chun, Severine Banek, Mike Wenzel, Markus Graefen, Thomas Steuber, Derya Tilki, Philipp Mandel
• Format: Article
• Language: English
• Published: Elsevier 2021-09-01
• Series: Prostate International
• Subjects: Local therapy; Metastasis-directed therapy; Oligometastatic; Prostate cancer; Systemic therapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S2287888221000027

Probably, patients with de novo (synchronous) and recurrent (metachronous) oligometastatic hormone-sensitive prostate cancer have different oncologic outcomes. Thus, we are challenged with different scenarios in clinical practice, where different treatment options may apply. In the last years, several prospective studies have focused on the treatment of patients with de novo oligometastatic hormone-sensitive prostate cancer. Not only the addition of systemic therapeutic treatments, such as chemotherapy with docetaxel, abiraterone, enzalutamide, and apalutamide, next to androgen deprivation therapy, demonstrated to improve outcomes in these patients but also local therapy of the primary has been demonstrated to improve outcomes of low-volume metastatic disease. Next to radiotherapy, also radical prostatectomy has been reported as a feasible and safe treatment option. Additional metastasis-directed therapy in de novo metastatic disease is currently examined by four trials. In the recurrent metastatic setting, less data are available, and it remains uncertain if patients can be treated in the same way as synchronous oligometastatic disease. Metastasis-directed therapy has demonstrated to prolong outcomes, while data on survival are still missing.